PREOPANC-2
Regimen
- Experimental
- Total neoadjuvant FOLFIRINOX (oxali 85 + iri 180 + LV 400 + 5-FU 400 bolus + 2400 46h) q2w x 8 cycles, then surgery without adjuvant.
- Control
- Neoadjuvant gemcitabine + 36 Gy/15 fx chemoradiation (PREOPANC-1 regimen) followed by surgery + 4 cycles adjuvant gemcitabine.
Population
Resectable or borderline resectable PDAC, ECOG 0-1, Dutch multicenter, enrolled 2018-2021.
Key finding
PREOPANC-2 showed total neoadjuvant FOLFIRINOX does not improve OS vs neoadjuvant gemcitabine-chemoradiation + adjuvant gemcitabine in resectable/borderline PDAC. Both arms delivered similar outcomes, supporting either approach but failing to establish FOLFIRINOX-only neoadjuvant as clearly superior.
Source: PMID 40945523